AVEO Pharmaceuticals, Inc. Message Board

THIS COMPANY IS FACING A FRAUD CHARGE! Very important info about FDA request was not disclosed to shareholders. When you dont disclose very important info from FDA , you are engaged in fraud.

this looks interesting, just did some fast research on this company, so far so good.

No, I am not but I do state my opinion based on facts/data. Remember, less than 10% of new drugs that enter clinic make it to the market. So we need to be real careful in investment dollars and choose the credible companies/management. Aveo is not!

In a highly regulated pharma/biotech world, when credibility is lost everything is lost except if you are a big pharma and has lots of cash to overcome the loss in a short period of time. I think that the whoever advised the CEO about this strategy must be fired. The CEO, from his bio, has not brought any drug to market or has no drug development experience but the people who report to him claim to have these qualities so the CEO may be innocent here but others who are fake must go.

From the past precedence, such as GPC biotech, the AVEO credibility is lost!!! That measn everything is lost and this will go the way GPC biotech went!!!

So according to your review of all the news, including the FDA ODAC meetings, law suit descriptions etc, you think trial design failure was the sole reason for these law suits?
Here the mistake was not to disclose key information (material to stock holders) conveyed during the pre-NDA meeting i.e. before filing the NDA submission. In other words, the investors would have known its a no go for the Tivo at least one year ago instead of waiting for one year and going through all the ODAC drama.

And if your holding long the stock what do you have to gain by pushing share prices down with frevelous lawsuits. They should be concentrating on getting TIVO approved and bring share prices UP for there stock holders not this #$%$.. IMO..

AVEO Pharmaceuticals, Inc. : AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 American Society of Clinical Oncology Annual Meeting.AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that additional data from the Phase 3 TIVO-1 trial (TIvozanib Versus sOrafenib in 1st line advanced RCC) of investigational agent tivozanib in patients with advanced renal cell carcinoma (RCC) will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, May 31 - June 4, 2013.

Sentiment: Strong Buy

Exactly. I think it is quite arguable that the FDA recommendation was material and should have been disclosed. They deserve to be sued imho - at a minimum to punish and discourage such behavior.

The main merit is that they didn't release to the public that the FDA had recomended a new trial in May 2012. The other stuff is BS. They also have insurance against these lawsuits, and they make the lawyers rich, but don't do much for the stockholders-its pennies on the dollar on losses, they also don't effect the company much.

Actually I think we head back to $2.50/shr. Bought at $2.35, sold at $3

Stop it.... Your posting shorts on other boards aswell.... Just read your post on PPHM...

greenmars the fool on "IGNORE"! BYEBYE!